| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.2K | 9.0% | 1.6% |
| Total Income | 1.2K | 10.6% | 1.5% |
| Expenditure | 1.1K | 8.7% | 1.2% |
| PBT | 154.16 | 26.4% | 20.8% |
| Net Profit | 131.52 | 24.6% | 40.4% |
| OPM | 18.25% | 0.48pp | 21.03pp |
| NPM | 10.54% | 1.18pp | 1.88pp |
| EPS | 13.84 | 28.0% | 36.5% |
Strides Pharma Science Ltd Delivers Robust Q2FY26 with Highest Ever Quarterly EPS
31 Oct 2025 · 31 Oct 2025, 01:09 pm
Summary
Strides Pharma Science Ltd has announced its consolidated financial results for the quarter (Q2FY26) and half year (H1FY26) ended September 30, 2025. The company reported a revenue of 12,208 million, a gross margin of 7,056 million, and an operational PAT of 1,403 million. The performance was primarily driven by the Other Regulated Markets. The company's focus on profitability enabled the gross margin growth of 15% YoY, and EBITDA growth of 25% YoY. Operational PAT stood at 1,403 million, up 84% YoY, with EPS rising to 15.2 for the quarter.
Key Highlights
- 1
Revenue at 12,208 million, grew 4.6% YoY
- 2
Absolute gross margin at 7,056 million, grew 14.6% YoY
- 3
Gross margin improved to 57.8%, up 500bps YoY
- 4
EBITDA grew 25.4% YoY to 2,316 million, EBITDA margin at 19.0%, grew 320bps YoY
- 5
Other Regulated Markets revenue at $44m, delivered strong growth of 16% YoY
- 6
Operational PAT at 1,403 million, Grew 84.3% YoY
- 7
Operational EPS at 15.2
Management Comments
Badree Komandur
MD & Group CEO
Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the Other Regulated Markets. Our focus on profitability enabled the gross margin growth of 15% YoY, and EBITDA growth of 25% YoY. Operational PAT stood at %1,403m, up 84% YoY, with EPS rising to 15.2 for the quarter.
Informational and educational content only. Not investment advice.